Chemomab Therapeutics Ltd.
CMMBNasdaqHealthcare · Pharmaceutical Preparations · L3 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | −$27.6M | −$12.5M | −$6.0M | −$27.1M | −$13.8M |
| Total assets | $43.1M | $64.4M | $12.5M | $19.8M | $12.8M |
| Total liabilities | $6.8M | $2.9M | $1.7M | $4.8M | $3.0M |
| Equity | $36.2M | $61.5M | $10.8M | $12.4M | $9.8M |
| EPS (diluted) | $0.12 | $0.06 | — | — | — |
| Shares out. | 221.0M | 37.1M | 37.1M | 37.1M | 15.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- −76.3%
- Return on assets
- −64.2%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 15.9%
- Debt / equity
- 0.19×
- Book value / share
- $0.16
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Accruals / assets
- −16.9%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 2 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Thiel PeterPassive (13G)Feb 17, 2026
- Otto ErikPassive (13G)Feb 10, 2026
- Morgan StanleyPassive (13G)Aug 7, 2025
- Orbimed Israel Biofund Gp Limited PartnershipActivist (13D)Jun 23, 2025
- Sphera Funds Management Ltd.Passive (13G)Apr 10, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 39,649 | 1.0 | -16.3% |
| Apr 30, 2026 | 47,374 | 1.3 | -5.8% |
| Apr 15, 2026 | 50,281 | 1.4 | +6.0% |
| Mar 31, 2026 | 47,427 | 1.0 | +16.3% |
| Mar 13, 2026 | 40,790 | 1.0 | -25.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeJun 16, 2023
- Director / officer change · Regulation FD disclosureJun 5, 2023
- Results of operationsMay 11, 2023
- Other material eventFeb 21, 2023
- Results of operationsFeb 21, 2023
- Regulation FD disclosureJan 11, 2023
- Other material eventJan 3, 2023
- Other material eventNov 16, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.